Rathbones Group PLC Reduces DexCom Stake by 79.9%

The investment firm cut its holdings in the medical device company during the third quarter.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Rathbones Group PLC, an investment management firm, reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 79.9% during the third quarter, according to a recent SEC filing. The firm now owns 138,523 shares of the medical device company's stock, valued at $9.32 million, after selling 551,828 shares.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are an important tool for diabetes management. Institutional investors' holdings in the company can provide insights into market sentiment and expectations around DexCom's performance and growth potential.

The details

Rathbones Group PLC's reduced stake in DexCom comes as the medical device company's stock has seen some volatility in recent quarters. DexCom's share price reached a 52-week high of $89.98 last year but has since declined to around $68 per share.

  • Rathbones Group PLC filed its Q3 2025 Form 13F with the SEC, disclosing the reduced DexCom stake.
  • DexCom's stock price reached a 52-week high of $89.98 in 2025.

The players

Rathbones Group PLC

An investment management firm based in the United Kingdom.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Rathbones Group's reduced stake in DexCom could signal broader market concerns about the medical device company's near-term performance, despite its long-term growth potential in the diabetes management space. Investors will likely continue to monitor DexCom's stock price movements and institutional ownership changes for clues about the company's outlook.